PTHS Revenue Flow
Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.
- 2026-06-30: Revenue $15.60M; Cost of revenue $3.61M; Research and development $600.00K; Selling, general and administrative $27.67M.
- 2026-03-31: Revenue $10.91M; Cost of revenue $1.67M; Research and development $186.00K; Selling, general and administrative $21.10M.
- 2025-12-31: Revenue (m); Cost of revenue $1.67M*; Research and development $374.00K*; Selling, general and administrative $18.47M*.
- 2025-09-30: Revenue (m); Cost of revenue $2.32M; Research and development $145.00K; Selling, general and administrative $19.63M.
Consolidation item
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Product or service
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Segment
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.
Historical revenue and expense breakdown
Revenue and expense 3 month
| Period end | Revenue | Cost of revenue | Research and development | Selling, general and administrative | Operating expenses | Income tax | Net income |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $15.60M | $3.61M | $600.00K | $27.67M | (m) | $0.00 | -$23.42M |
| 2026-03-31 | $10.91M | $1.67M | $186.00K | $21.10M | (m) | $0.00 | -$25.07M |
| 2025-12-31 | (m) | $1.67M* | $374.00K* | $18.47M* | (m) | -$6.92M* | -$21.66M* |
| 2025-09-30 | (m) | $2.32M | $145.00K | $19.63M | $22.77M | -$465.00K | -$16.24M |
| 2025-06-30 | $0.00 | $0.00 | $515.00K | $2.72M | $3.23M | $0.00 | -$3.45M |
| 2025-03-31 | $0.00 | $0.00 | $194.00K | $1.64M | $1.83M | $0.00 | -$1.97M |
| 2024-09-30 | (m) | (m) | $415.00K | $1.63M | $2.05M | (m) | -$1.70M |
| 2024-06-30 | (m) | (m) | $12.96K | (m) | $1.76M | (m) | -$1.77M |
| 2024-03-31 | (m) | (m) | $466.61K | (m) | $1.93M | (m) | -$2.56M |
| 2023-09-30 | (m) | (m) | $49.13K | (m) | $1.29M | (m) | -$1.42M |
| 2023-06-30 | (m) | (m) | $49.95K | (m) | $777.16K | (m) | -$953.35K |
| 2023-03-31 | (m) | (m) | $186.12K | (m) | $914.58K | (m) | -$966.56K |
Revenue and expense 6 month
| Period end | Revenue | Cost of revenue | Research and development | Selling, general and administrative | Operating expenses | Income tax | Net income |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $26.51M | $5.28M | $786.00K | $48.78M | (m) | $0.00 | -$48.49M |
| 2025-06-30 | $0.00 | $0.00 | $709.00K | $4.36M | $5.06M | $0.00 | -$5.42M |
| 2024-06-30 | (m) | (m) | $479.56K | (m) | $3.70M | (m) | -$4.33M |
| 2023-06-30 | (m) | (m) | $236.07K | (m) | $1.69M | (m) | -$1.92M |
Revenue and expense 9 month
| Period end | Revenue | Cost of revenue | Research and development | Selling, general and administrative | Operating expenses | Income tax | Net income |
|---|---|---|---|---|---|---|---|
| 2025-09-30 | (m) | $2.32M | $854.00K | $23.98M | $27.83M | -$465.00K | -$21.66M |
| 2024-09-30 | (m) | (m) | $894.00K | $4.85M | $5.75M | (m) | -$6.03M |
| 2023-09-30 | (m) | (m) | $285.20K | (m) | $2.98M | (m) | -$3.34M |
Revenue and expense 12 month
| Period end | Revenue | Cost of revenue | Research and development | Selling, general and administrative | Operating expenses | Income tax | Net income |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $16.80M | $3.99M | $1.23M | $42.45M | (m) | -$7.39M | -$43.32M |
| 2024-12-31 | $0.00 | $0.00 | $1.18M | $6.39M | $7.57M | $0.00 | -$7.96M |
| 2023-12-31 | (m) | (m) | $2.58M | (m) | $6.86M | (m) | -$7.38M |
| 2022-12-31 | (m) | (m) | $391.73K | (m) | $2.32M | (m) | -$2.46M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |